Reduction the Duration of Antibiotic Therapy in the Elderly (PROPAGE)

Not Applicable

Terminated

• Conditions: Lung Infection
• Interventions: Other: procalcitonine

• Registration Number: NCT02173613
• Lead Sponsor: University Hospital, Grenoble

Brief Summary

The main objective is to evaluate the interest of the repeated measurement of procalcitonin in patients with pulmonary infection to reduce the duration of antibiotic therapy in comparison with a conventional clinical strategy.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-08
• Study First Submitted: 2013-06-20
• Study First Submitted QC: 2014-06-20
• Study First Posted: 2014-06-25
• Primary Completion: 2015-12
• Status Verified: 2016-02
• Study Completion: 2016-03
• Last Update Submitted: 2022-04-25
• Last Update Posted: 2022-05-02

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 117

Inclusion Criteria

• Age ≥ 80 years
• Started antibiotics for a chest infection
• Procalcitonin performed J0 antibiotic treatment
• Person affiliated to the social security

Exclusion Criteria

• Patients with a documented infection with germs after Listeria spp, Legionella pneumophilia, Mycobacterium tuberculosis
• Patients with a documented infection with a virus or parasite (eg hemorrhagic fever, malaria)
• Patients with endovascular infection associated (endocarditis, pacemaker. Intravascular catheter)
• Patients with lung abscess associated upon entry Patients with a chronic infection associated
• Patients with severe immunosuppression (HIV or transplant)
• Palliative patient
• Death within 24 hours of admission to nursing units.
• Presence of antibiotic treatment for chronic infection.
• Patient under guardianship, curatorship or any other administrative or judicial action or deprivation of the right or freedom
• Patients hospitalized without their consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Procalcitonine	procalcitonine	every 2 days, they will receive the dose of PCT and decide to stop antibiotic treatment according to the algorithm 2. They will notify the results of clinical evaluations in the electronics and all adverse event report forms.

Primary Outcome Measures

Name	Time	Method
Duration of antibiotic therapy	Success of antibiotic therapy within 45 days of inclusion

Trial Locations

Locations (1)

University Hospital Grenoble; 🇫🇷 Grenoble, Rhone Alpes, France